These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28978569)

  • 21. A close insight to factor VIII inhibitor in the congenital hemophilia A.
    Tabriznia-Tabrizi S; Gholampour M; Mansouritorghabeh H
    Expert Rev Hematol; 2016 Sep; 9(9):903-13. PubMed ID: 27367203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
    Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
    FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
    Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
    Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries.
    Schmidt A; Brettschneider K; Kahle J; Orlowski A; Becker-Peters K; Stichel D; Schulze J; Braner M; Tampé R; Schwabe D; Königs C
    Thromb Haemost; 2016 Jul; 116(1):32-41. PubMed ID: 27009573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.
    Wootla B; Dasgupta S; Dimitrov JD; Bayry J; Lévesque H; Borg JY; Borel-Derlon A; Rao DN; Friboulet A; Kaveri SV; Lacroix-Desmazes S
    J Immunol; 2008 Jun; 180(11):7714-20. PubMed ID: 18490775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.
    Parvathaneni K; Scott DW
    Blood Adv; 2018 Sep; 2(18):2332-2340. PubMed ID: 30232086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The humoral response to human factor VIII in hemophilia A mice.
    Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
    J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
    Ramakrishnan R; Davidowitz A; Balu-Iyer SV
    J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
    Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
    Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice.
    Meslier Y; André S; Teyssandier M; Kaveri SV; Lacroix-Desmazes S
    Immunology; 2010 Dec; 131(4):549-55. PubMed ID: 20673239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A.
    Kruse-Jarres R
    Hematology Am Soc Hematol Educ Program; 2011; 2011():407-12. PubMed ID: 22160066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.
    Matino D; Gargaro M; Santagostino E; Di Minno MN; Castaman G; Morfini M; Rocino A; Mancuso ME; Di Minno G; Coppola A; Talesa VN; Volpi C; Vacca C; Orabona C; Iannitti R; Mazzucconi MG; Santoro C; Tosti A; Chiappalupi S; Sorci G; Tagariello G; Belvini D; Radossi P; Landolfi R; Fuchs D; Boon L; Pirro M; Marchesini E; Grohmann U; Puccetti P; Iorio A; Fallarino F
    J Clin Invest; 2015 Oct; 125(10):3766-81. PubMed ID: 26426076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Detection of alloantibodies against Factor VIII in plasma of patients with hemophilia A and its relationship with Factor VIIIC domain].
    Zhang LL; Yu ZQ; Wan CC; Zhang W; Zhang ZH; Ruan CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1211-4. PubMed ID: 24156436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII.
    Dimitrov JD; Dasgupta S; Navarrete AM; Delignat S; Repesse Y; Meslier Y; Planchais C; Teyssandier M; Motterlini R; Bayry J; Kaveri SV; Lacroix-Desmazes S
    Blood; 2010 Apr; 115(13):2682-5. PubMed ID: 19890094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.
    Hausl C; Ahmad RU; Sasgary M; Doering CB; Lollar P; Richter G; Schwarz HP; Turecek PL; Reipert BM
    Blood; 2005 Nov; 106(10):3415-22. PubMed ID: 16091456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catalytic activity of antibodies against factor VIII in patients with hemophilia A.
    Lacroix-Desmazes S; Moreau A; Sooryanarayana ; Bonnemain C; Stieltjes N; Pashov A; Sultan Y; Hoebeke J; Kazatchkine MD; Kaveri SV
    Nat Med; 1999 Sep; 5(9):1044-7. PubMed ID: 10470082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reprogrammed CD4
    Herzog RW; Kuteyeva V; Saboungi R; Terhorst C; Biswas M
    Front Immunol; 2019; 10():274. PubMed ID: 30842776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
    Liu CL; Ye P; Yen BC; Miao CH
    Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.